Replies to post #19265 on American Bio Medica Corp (ABMC)

[skankhuntfortytwo]

It was the 10-Q:

The First Quarter 2020 did not include any revenues from the sale of Covid-19 rapid antibody tests. Although we were able to generate prepaid, pre-sales of the Covid-19 tests late in the First Quarter 2020, we did not start shipping products and generate revenue until May 2020. Prior to May 2020, there were a number of regulatory events that resulted in an inability to get the supply of products from the manufacturing plant in China. Once those events were addressed, we were able to receive product and ship orders to customers. As of the date of this report, we have shipped $1,126,000 in products to customers and there are additional orders pending from customers.

So, In reading this again I guess they were able to clear up all the issues that had limited their ability to receive the supply of tests. Maybe a different question, Do they anticipate those same challenges occurring in Q2 and beyond?

[The Rainbow]

These regulatory issues were between the US and China. Trump vs the world and have nothing to do with shipping or inventory problems.

We get materials as soon as they are available.